Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors
Authors:
Open Access
- 28 April 2015
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 159
Abstract
The human polyomavirus JC PyV lytic infection of oligodendrocytes in the human brain results in the demyelinating disease progressive multifocal leukoencephalopathy, PML. JCV is a common virus infection in the population that leads to PML in patients with underlying diseases and therapies that cause immune deficiencies or modulate immune system functions. Patients may have high levels of antibody to JCV that does not protect them from PML nor clear the infection once PML is established. Cell mediated immunity plays a more effective role in clearing initial or reactivated JCV infection before PML occurs. However patients with underlying diseases and therapies for treatment are at high risk for PML. MS patients on natalizumab are one of the categories with the highest incidence of PML. Natalizumab is a humanized monoclonal antibody targeting α4 integrins that prevents inflammatory cells from entering the brain and it has been used as a treatment for MS. A number of studies have investigated the occurrence of PML in these patients and their cell mediated immune profile that might gain insight into the mechanism that ties natalizumab with a high risk of developing PML. It seems that cells of the immune system participate in the pathogenesis of PML as well as clearance of JCV infection.Keywords
This publication has 45 references indexed in Scilit:
- Immunological Hallmarks of JC Virus Replication in Multiple Sclerosis Patients on Long-Term Natalizumab TherapyJournal of Virology, 2013
- Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal LeukoencephalopathyPLOS Pathogens, 2012
- JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytesJournal of General Virology, 2012
- Role of CD4 + and CD8 + T-Cell Responses against JC Virus in the Outcome of Patients with Progressive Multifocal Leukoencephalopathy (PML) and PML with Immune Reconstitution Inflammatory SyndromeJournal of Virology, 2011
- Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activityJournal of General Virology, 2010
- JC Virus Infection A Cause of Colorectal Cancer?Journal of Clinical Gastroenterology, 2010
- Molecular Regulation of JC Virus Tropism: Insights into Potential Therapeutic Targets for Progressive Multifocal LeukoencephalopathyJournal of Neuroimmune Pharmacology, 2010
- Determinants of survival in progressive multifocal leukoencephalopathyNeurology, 2009
- Asymptomatic Reactivation of JC Virus in Patients Treated with NatalizumabNew England Journal of Medicine, 2009
- Detection of JC Virus DNA and Proteins in the Bone Marrow of HIV‐Positive and HIV‐Negative Patients: Implications for Viral Latency and Neurotropic TransformationThe Journal of Infectious Diseases, 2009